ATLANTA, July 16, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its contract for the use of RevID with a 425-bed, Oracle-EHR based health system and extended the term for an additional 5 years.
Streamline Health is leading an industry movement to improve hospital financial performance through pre-bill technology solutions. RevID’s automated charge reconciliation accelerates cash flow by ensuring that providers can accurately capture, bill and ultimately be paid for all the care they provide.
“We are pleased with the continued trust our client places in our products and our team,” stated Ben Stilwill, President and Chief Executive Officer, Streamline. “We look forward to supporting their quest to be accurately paid for all of the care they’ve provided and sharing their experience with future clients.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
| Last Trade: | US$5.33 |
| Daily Volume: | 0 |
| Market Cap: | US$23.240M |
May 01, 2025 January 22, 2025 December 18, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
